The Shadow of DES: Understanding the Ongoing Impact of Diethylstilbestrol Litigation
In the 1970s, a storm of litigation began to brew, centered around a drug called Diethylstilbestrol, or DES. This synthetic estrogen, prescribed to millions of pregnant women between the 1940s and 1971 to prevent miscarriages, was later found to cause serious health problems in their children. This article delves into the complexities of DES (Diethylstilbestrol) Litigation (1970s) and settlements for pharmaceutical injuries, exploring the history, legal challenges, and lasting impact of this tragic chapter in medical history.
A “Wonder Drug” Gone Wrong
Initially hailed as a “wonder drug,” DES was aggressively marketed to physicians, with some even recommending it for all pregnancies to ensure healthier babies. However, this widespread use occurred despite early warning signs and evidence suggesting the drug was ineffective in preventing miscarriages and caused cancer in animals. Tragically, these concerns were largely ignored, leading to widespread exposure and devastating consequences.
The Discovery of the Dark Side
In 1971, the link between DES and a rare form of vaginal cancer, clear-cell adenocarcinoma (CCA), in young women was finally established. This discovery prompted the FDA to withdraw its approval of DES for use in pregnant women. However, the damage was already done. Millions of “DES daughters” and “DES sons” had been exposed to the drug in utero, facing an increased risk of various health issues throughout their lives.
Health Consequences Across Generations
The legacy of DES extends beyond the initial generation of users. The health effects have impacted DES mothers, their children (DES daughters and sons), and potentially even their grandchildren.
- DES Mothers: Face a slightly increased risk of breast cancer.
- DES Daughters: Have a significantly higher risk of developing CCA of the vagina and cervix, as well as reproductive abnormalities, infertility, ectopic pregnancy, preterm delivery, and spontaneous abortion. Some studies suggest an elevated risk of pancreatic cancer.
- DES Sons: May experience genital defects, infertility issues, and potentially elevated risks of cancer and cardiovascular problems.
- DES Grandchildren: Emerging evidence suggests potential health impacts on the third generation, though research is ongoing.
The Legal Battles Begin: DES Litigation (1970s)
The revelation of DES’s harmful effects sparked a wave of lawsuits against the drug’s manufacturers. These cases presented unique legal challenges, primarily due to the long latency period between exposure and the onset of health problems.
Statute of Limitations
One of the most significant hurdles in DES litigation has been the statute of limitations. This legal principle sets a time limit within which a lawsuit must be filed after an injury occurs. In many DES cases, the symptoms and diagnoses appeared years, even decades, after the initial exposure, making it difficult to meet the traditional statute of limitations requirements.
However, courts have recognized the unfairness of applying the standard statute of limitations in these cases and have adopted the “discovery rule.” This rule states that the statute of limitations does not begin to run until the victim knows or reasonably should have known about the injury and its connection to the drug.
Identifying the Responsible Party
Another major challenge in DES litigation is identifying the specific manufacturer of the drug taken by a plaintiff’s mother. Given that DES was produced and distributed by numerous companies over several decades, it’s often impossible to pinpoint the exact source.
To address this issue, some courts have adopted the “market share liability” theory. This principle allows plaintiffs to sue multiple DES manufacturers, and each company’s liability is proportional to its share of the DES market at the time the drug was sold. The landmark case of Sindell v. Abbott Laboratories (1980) in California established this doctrine, paving the way for many DES-affected individuals to seek compensation.
Settlements for Pharmaceutical Injuries: Seeking Justice and Compensation
While no amount of money can undo the harm caused by DES, settlements and jury awards have provided some measure of justice and financial support to victims. Compensation in DES cases typically covers:
- Medical expenses
- Lost wages
- Emotional distress
- Loss of enjoyment of life
- Punitive damages (in some cases, to punish the manufacturer for their wrongful conduct)
Notable Settlements and Verdicts
- In 1991, a New York state court jury awarded Margaret Perrotte $12.2 million in damages from Eli Lilly & Co., the largest verdict ever in a DES case at the time.
- In 2002, two French women won their case against UCB Pharma, the manufacturer of Distilbène (the brand name for DES in France), and were awarded €15,244 each as an interim payment.
- In the Netherlands, lawsuits against several laboratories led to the creation of a compensation fund of €35 million.
- In 2013, Eli Lilly and Co. reached a settlement with four sisters who claimed their breast cancer was caused by their mother’s DES use. The settlement amount was not disclosed.
The Situation Today
DES is rarely used today. While the FDA banned DES for pregnant women in 1971, the drug continued to be prescribed for other conditions for some time.
Ongoing Litigation and Advocacy
Although the peak of DES litigation has passed, cases continue to emerge as new health problems develop in DES-exposed individuals. Advocacy groups like DES Action USA continue to provide support, education, and resources to those affected by DES.
The UK Perspective
Unlike the US, the UK has seen limited legal action regarding DES. There have been no successful class-action lawsuits, and the government has not issued a formal apology or established a compensation fund for victims. However, organizations like the Jackson Lees Group are actively campaigning for government action, including a public inquiry and compensation scheme.
Lessons Learned and the Path Forward
The DES tragedy serves as a stark reminder of the potential dangers of pharmaceutical products and the importance of rigorous testing and monitoring. It also highlights the need for:
- Strong regulatory oversight: To ensure the safety and efficacy of drugs before they are widely prescribed.
- Transparency and disclosure: Pharmaceutical companies must be transparent about the risks associated with their products and provide adequate warnings to patients and healthcare providers.
- Access to justice: Legal systems must be responsive to the needs of victims of pharmaceutical injuries, particularly in cases involving long latency periods and complex causation issues.
- Continued research: Further research is needed to fully understand the long-term health effects of DES exposure and to develop effective strategies for prevention and treatment.
The DES story is a complex and multifaceted one, filled with scientific discovery, medical innovation, legal battles, and human tragedy. By understanding the history and ongoing impact of DES, we can work to prevent similar tragedies from occurring in the future and ensure that those affected receive the support and justice they deserve.